An NDIS participant with a chronic condition can enjoy a taxpayer-supported cruise with their support team. Does it make sense that, at the same time, they could be denied funded access to medicine or other health technology that could significantly improve their health and quality of life? Where is the equity and opportunity cost in that?
Should principles such as 'equity' and 'opportunity cost' be applied consistently or not at all?
April 23, 2024 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Company size shapes CEO pay trends in Australian health care and biotechnology
October 6, 2026 - - Latest News -
Young NZ cancer patients to get funded medicines no matter where they are treated
October 6, 2026 - - Latest News -
TGA turns to national security surveillance platform to police therapeutic goods compliance
October 6, 2026 - - Latest News -
CSL announces investment for share of Alentis rare kidney and liver candidate
October 6, 2026 - - Latest News -
TGA approves Roche's refillable eye implant for wet macular degeneration
October 5, 2026 - - Latest News -
The 'Dispatched' Podcast Week in Review - Series 5. Ep.34
October 2, 2026 - - Podcast -
Under the TGA's new rules, the safest story is one without the patient experience
October 2, 2026 - - Latest News
